This once-daily topical treatment is the latest phosphodiesterase-4 (PDE4) inhibitor designed for mild to moderate atopic ...

The FDA has accepted the biologics licensing application (BLA) resubmission for odronextamab, a potential treatment for ...

MedImpact Healthcare Systems, the nation’s largest independent provider of health solutions, technology, and pharmacy benefit ...

然而，三星Bioepis近日与一家未透露名称的“垂直整合健康集团”达成合作，提前以自有品牌销售其仿制药Pyzchiva，并于本周一正式上市。强生指控此举“明显违反协议”，构成“秘密且故意的违约行为”，可能对Stelara的市场份额造成“不可逆的损害”。